{
    "clinical_study": {
        "@rank": "14919", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "CONDITIONING: Patients receive carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.\nTRANSPLANT: Patients undergo autologous stem cell transplant on day 0."
        }, 
        "brief_summary": {
            "textblock": "This phase I/II trial studies the side effects and best dose of carfilzomib when given\n      together with melphalan and to see how well they work in treating patients with multiple\n      myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes\n      needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different\n      ways to stop the growth of cancer cells, either by killing the cells or by stopping them\n      from dividing. Giving carfilzomib together with melphalan may kill more cancer cells."
        }, 
        "brief_title": "Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma", 
        "condition": [
            "Refractory Multiple Myeloma", 
            "Stage I Multiple Myeloma", 
            "Stage II Multiple Myeloma", 
            "Stage III Multiple Myeloma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the maximum tolerated dose (MTD) of carfilzomib that can be added to high\n      dose melphalan as part of conditioning chemotherapy for myeloma. (Phase I) II. To determine\n      the efficacy of the combination in patients with myeloma undergoing stem cell\n      transplantation, as defined by achievement of complete response (CR). (Phase II)\n\n      SECONDARY OBJECTIVES:\n\n      I. To examine the toxicities associated with addition of carfilzomib to high dose melphalan\n      in patients with multiple myeloma (MM).\n\n      II. To determine the progression free rate at 1 and 2 years post registration.\n\n      TERTIARY OBJECTIVES:\n\n      I. To determine the proportion of patients achieving a minimal residual disease (MRD)\n      negative status.\n\n      II. To assess the HevyLite assay prior to and during treatment.\n\n      OUTLINE:\n\n      CONDITIONING: Patients receive carfilzomib intravenously (IV) over 30 minutes on days -6,\n      -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3.\n\n      TRANSPLANT: Patients undergo autologous stem cell transplant on day 0.\n\n      After completion of study treatment, patients are followed up at day 30, day 100, and then\n      every 90 days for up to 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Serum creatinine =< 2 mg/dL\n\n          -  Absolute neutrophil count >= 1000/\u03bcL\n\n          -  Platelet count >= 50,000/\u03bcL\n\n          -  Hemoglobin >= 8.0 g/dL\n\n          -  Diagnosis of symptomatic MM\n\n          -  Measurable disease of multiple myeloma at the time of baseline values for disease\n             assessment as defined by at least one of the following:\n\n               -  Serum monoclonal protein >= 1.0 g/dL\n\n               -  >= 200 mg of monoclonal protein in the urine on 24 hour electrophoresis\n\n               -  Serum immunoglobulin free light chain >=10 mg/dL AND abnormal serum\n                  immunoglobulin kappa to lambda free light chain ratio\n\n               -  Bone marrow plasma cells >= 30%\n\n               -  NOTE: For patients with no relapse prior to transplant, measurable disease at\n                  the time of diagnosis\n\n               -  NOTE: For patients who have had a disease relapse prior to transplant,\n                  measurable disease at the time of the most recent relapse immediately prior to\n                  transplant; NOTE: If the patient had treatment for the relapsed disease prior to\n                  transplant, the patient must have measurable disease at the time of relapse\n                  prior to this therapy\n\n          -  Patient is considered for autologous stem cell transplantation with full dose\n             melphalan (200 mg/m2)\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n\n          -  Recovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and\n             hematological toxicity)\n\n          -  Provide informed written consent\n\n          -  Ejection fraction >= 45%\n\n          -  Corrected pulmonary diffusion capacity of greater than or equal to 50%\n\n          -  Forced expiratory volume in 1 second (FEV1) >= 50%\n\n          -  Forced vital capacity (FVC) >= 50%\n\n          -  Negative pregnancy test performed =< 7 days prior to registration, for women of\n             childbearing potential only\n\n          -  Willing to return to Mayo Clinic Rochester, Mayo Clinic Arizona, or Mayo Clinic\n             Florida for treatment and follow-up\n\n               -  Note: During the Active Monitoring Phase of a study (i.e., active treatment and\n                  observation), participants must be willing to return to the consenting\n                  institution for follow-up\n\n          -  Willing to provide blood and bone marrow samples for correlative research purposes\n\n        Exclusion Criteria:\n\n          -  Prior autologous or allogeneic bone marrow/peripheral blood stem cell transplant\n\n          -  More than two prior regimens for therapy of MM\n\n          -  Myocardial infarction within 6 months prior to enrollment, or has New York Heart\n             Association (NYHA) class III or IV heart failure, uncontrolled angina, severe\n             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute\n             ischemia or active conduction system abnormalities; NOTE: Prior to study entry, any\n             ECG abnormality at screening has to be documented by the investigator as not\n             medically relevant\n\n          -  Seroreactivity for human immunodeficiency virus (HIV), human T-lymphotropic virus\n             (HTLV) I or II, hepatitis B virus (HBV), hepatitis C virus (HCV)\n\n          -  Other active malignancy < 2 years prior to registration; EXCEPTIONS: Non-melanotic\n             skin cancer or carcinoma-in-situ of the cervix; NOTE: If there is a history or prior\n             malignancy, they must not be receiving other specific treatment for their cancer\n\n          -  Any of the following:\n\n               -  Pregnant women or women of reproductive capability who are unwilling to use\n                  effective contraception\n\n               -  Nursing women\n\n               -  Men who are unwilling to use a condom (even if they have undergone a prior\n                  vasectomy) while having intercourse with any woman, while taking the drug and\n                  for 28 days after stopping treatment\n\n          -  Other co-morbidity, which would interfere with patient's ability to participate in\n             the trial, e.g. uncontrolled infection, uncompensated lung disease\n\n          -  Concurrent chemotherapy, radiotherapy, or any ancillary therapy considered\n             investigational; NOTE: Bisphosphonates are considered to be supportive care rather\n             than therapy, and are thus allowed while on protocol treatment\n\n          -  Known allergies to any of the components of the investigational treatment regimen or\n             required ancillary treatments"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "68", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842308", 
            "org_study_id": "MC1185", 
            "secondary_id": "NCI-2013-00550"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "description": "Given IV", 
                "intervention_name": "carfilzomib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Kyprolis", 
                    "PR-171"
                ]
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Given IV", 
                "intervention_name": "melphalan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Alkeran", 
                    "CB-3025", 
                    "L-PAM", 
                    "L-phenylalanine mustard", 
                    "L-Sarcolysin"
                ]
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Undergo autologous stem cell transplant", 
                "intervention_name": "autologous bone marrow transplantation", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "ABMT", 
                    "bone marrow transplantation, autologous", 
                    "transplantation, autologous bone marrow"
                ]
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Undergo autologous stem cell transplant", 
                "intervention_name": "autologous hematopoietic stem cell transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Treatment", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melphalan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 28, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224"
                    }, 
                    "name": "Mayo Clinic - Florida"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)", 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Suzanne Hayman", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum tolerated dose (MTD), defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least one-third of patients (Phase I)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to day 30"
            }, 
            {
                "description": "The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated.", 
                "measure": "Proportion of complete responses, defined as a CR noted as the objective status on two consecutive evaluations (Phase II)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842308"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimated by the total number of patients who achieve a complete response by day 100 post-transplant divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true complete response rate at day 100 will be calculated.", 
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "At day 100"
            }, 
            {
                "description": "The distribution of time to progression will be estimated using the method of Kaplan-Meier.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to the earliest date with documentation of disease progression, assessed at 1 year"
            }, 
            {
                "description": "The distribution of time to progression will be estimated using the method of Kaplan-Meier.", 
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from registration to the earliest date with documentation of disease progression, assessed at 2 years"
            }, 
            {
                "description": "The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.", 
                "measure": "Adverse event rate, graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}